Two common mutations in AML, with significant impacts on prognosis, include the mutations in the nucleophosmin 1 (NPM1) gene and the internal tandem duplications (ITD) of the fms-related tyrosine kinase 3 (FLT3) gene [5,6,7,8,9]. This evidence concerns the gene NPM1 and acute myeloid leukemia.